Additional remetinostat phase II data will be presented at the International Investigative Dermatology meeting on May 18 and 19
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that additional data from the phase II study of remetinostat in patients with early stage cutaneous T-cell lymphoma (CTCL) will be presented during the International Investigative Dermatology (IID) meeting, which will take place from 16-19 May 2018 in Orlando, FL, USA. The focus of the presentation is the effect of remetinostat on reducing pruritis (itching), as seen in the phase II study. Remetinostat (previously called SHAPE) is Medivir’s proprietary topical HDAC inhibitor that is being developed for the treatment of